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INTRODUCTION: 
The nephrotic syndrome is probably the most common chronic 
renal illness in children. In Africa the nature of the renal 
lesions differs from the pattern seen in temperate areas1 • The 
main difference between Africa, and Europe and North America 
is the much higher incidence of glomerular pathology 
associated with infectious agents such as Lancefield group A 
steptococci, malaria and syphilis2 • Since the early 1980 's 
there has been an increasing awareness of children with 
nephrotic syndrome and concurrent hepatitis B virus (HBV) 
infection. This study was undertaken to investigate this 




In 1971 Combes et a1 3 described a 53 year old man who 
sustained severe injuries in a motor vehicle accident. He was 
resuscitated with 4 units of blood and 4 months later 
developed acute hepatitis. A year and a half after the 
accident he developed the nephrotic syndrome. His serum was 
found to be positive for hepatitis B surface antigen (HBsAg). 
Renal biopsy showed membranous glomerulonephritis. Immune 
deposits were positive for HBsAg using an indirect 
immunofluorescent technique. 
This was the first description of the hepatitis B virus (HBV) 
as a causative agent of glomerulonephritis. Since then several 
reports have been published4- 11 • Most authors have concentrated 
on the relationship of hepatitis B virus to membranous 
nephropathy (MGN) , but there does seem to be a relationship 
with mesangiocapillary glomerulonephritis (MCGN) as we11
12113 • 
The first South African report of a possible association 
between hepatitis B virus infection and glomerular disease was 
published in 1973 14 • Ten years later Wiggelinkhuizen et al 
published their series of 25 children with MGN associated with 
HBV infection seen at the Red Cross War Memorial Children's 
Hospital. 8 This paper was important for several reasons: 
Firstly it raised the level of awareness to the relatively 
high incidence of the condition in this country, and secondly 
it supported the relationship between resolution of the 
7 
nephrotic state and clearance of the hepatitis B e antigen 
(HBeAg) from the circulation. 
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controversy regarding causality: 
After the initial case report, papers began to appear 
reporting the incidence of hepatitis B carriage in patients 
with a variety of glomerulopathies and comparing this 
incidence to that of other populations, such as blood 
donors14 , 15 • The striking differences in incidence appeared to 
establish the pathogenic role of HBV on epidemiological 
grounds. 
However, in a population with a large number of people 
infected with HBV there are inevitably going to be patients 
who are incidental carriers of the virus, with other, 
unrelated diseases. The problem thus arises how to determine 
whether or not the glomerular lesion in any particular patient 
is causally related to the hepatitis B virus. Initially, 
demonstration of HBV antigens within immune complexes situated 
within the glomerulus was considered proof of the causal role 
of HBV. However in 1981 Maggiore et a1 16 described artifactual 
demonstration of HBsAg in glomeruli of patients whose serum 
was negative for HBV antigens. This was presumed to be due to 
non-specific binding to the crystallisable fragment (Fe) of 
the labelled antibody by anti-immunoglobulin antibodies within 
the immune deposits as this false-positive staining was 
eliminated when labelled antigen-binding fragments Fab 
directed against HBsAg were used. More recently, investigators 
in China tested a variety of renal biopsies for HBV antigens 
using monoclonal antibodies against HBsAg, HBcAg and HBeAg. 
They found no difference in antigen detection rates between 
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patients whose serum was positive for HBV antigens and those 
who were negative in a variety of glomerular pathologies . 17 
The deposition of HBV antigens followed the pattern of immune 
complex deposition, and massive immune complexes were usually 
positive for HBV antigens. In this study whole antibodies were 
used and not F <ab, ) 2 fragments as used by Hirose et al. 
18 Non-
specif c binding to the Fe fraction in these massive deposits 
is likely to have occured as in the study by Maggiore et al. 16 
A number of authors have reported being unable to demonstrate 
HBsAg in the glomeruli of patients who were suspected on 
clinical grounds of having HBV-related disease. 6- 8 Other 
authors, while demonstrating HBsAg inconsistently or not at 
all in these patients, obtained consistently positive results 
for HBeAg using highly specific antisera in those patients 
with active disease.1a-20 
It would appear then that demonstration of HBeAg within 
glomerular immune complexes may be the most accurate method of 
making a prospective diagnosis of hepatitis B nephropathy 
provided that highly specific methods are used. However 
Venkataseshan et a1 21 were able to demonstrate HBeAg in only 6 
of 12 patients. Moreover the antisera required are not readily 
available, and most clinicians make a diagnosis based on 
clinical, serological and histological grounds. In addition 
HBeAg deposits have not been sought in large numbers of 
patients. The best confirmation at present appears to be 
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retrospective, if resolution correlates with clearance of the 
HBV antigens from the serum. 
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AIMS: 
The aims of this study were as follows: 
1. ) To determine the importance of hepatitis B virus 
infection as a cause of glomerulonephritis at the Red 
Cross War Memorial Children's Hospital. 
2.) To describe the clinical, laboratory and 
histopathological features of the disease as seen by us. 
3.) To describe the natural history of the disease. 
4.) To attempt to define indicators of good or less 
favourable outcome. 
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TYPE OF STUDY: 
This is primarily a retrospective study, based largely on the 
examination of hospital records. However 9 of the patients 
presented after the decision had been made to conduct this 
study and they were studied prospectively. The study is partly 
descriptive and partly analytic. 
A small, uncontrolled interventional study was undertaken on 
the use of Interferon Alpha 2b in hepatitis B nephropathy. 
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PATIENTS AND METHODS: 
All patients with nephrotic syndrome seen by the Renal Service 
from 1 August 1969 up to the end of October 1990 were 
reviewed. The identities of these patients were obtained from 
several sources, viz: 
1.) Hospital computerised records of diagnoses 
2.) Renal Clinic folders 
3.) Renal biopsy reports 
4.) A data base of patients with nephrotic syndrome used in 
previous studies by Professor Jan Wiggelinkhuizen 
5.) A computerised data base of patients kept by Dr G. R. van 
Dugteren, a part-time consultant in the Renal Clinic. 
The hospital records of all these patients were reviewed, and 
those with other conditions excluded. The ethnic group, sex, 
diagnosis, and hepatitis B status were recorded in those who 
had evidence of nephrotic syndrome. For these purposes the 
nephrotic syndrome was defined as persistent 4+ proteinuria 
with hypo-albuminaemia (less than or equal to 25 g/1) and 
hypercholesterolaemia or quantified protein excretion of more 
than 40 mg/m2 /hour22 together with hypo-albuminaemia with or 
without hypercholesterolaemia. 
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Those with positive hepatitis B serology were then examined 
further and constitute the major part of this study. 
All available records (hospital and Renal Clinic) of the 72 
patients who were felt to have HBV related disease (defined 
below) were reviewed, and data collected on a computerised 
data base. These data included extensive clinical, 
demographic, laboratory and follow-up data (see appendix 1). 
The histopathology was reviewed and analysed according to a 
standardised protocol (appendix 2). The data obtained in this 
way were then subjected to analysis. Statistical analysis was 
done on an IBM compatible XT personal computer using 
STATGRAPHICS. 
Routine haematological, microbiological and biochemical tests 
were done in the diagnostic laboratories of the Red Cross War 
Memorial Children's Hospital. 
Renal function was estimated in 2 ways. Fifty (68%) patients 
had endogenous creatinine clearance studies performed shortly 
after presentation. In addition, corrected GFR was estimated 
from the serum creatinine at the time of first presentation 
and at the most recent Renal Clinic visit using the formula
23 : 
GFR = Height in cm x 38 
Plasma creatinine µmol/1. 
Body surface area for calculation of corrected creatinine 
clearance and proteinuria was obtained from the formula24 : 
BSA (cm2 ) = Wt01425 X Ht0 • 725 X 71,84 
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where BSA= body surface area, Wt= weight in kilograms and Ht 
= height in cm. 
Proteinuria selectivity index was calculated using the 
formula: 
Selectivity index(%)= Urine IgG x plasma albumin x 100 
Plasma IgG x urine albumin. 
Anaemia and microcytosis were defined as haemoglobin 
concentration and mean cell volume below the lower limit of 
normal for age as defined by Oski25 • 
Before 1976 HBsAg was detected by passive haemagglutination, 
and no test was available for HBeAg. Since then, 
radioimmunoassays have been used to detect HBsAg (Ausria II 
and Ausab, Abbott Laboratories) and HBeAg and antibodies 
directed against HbeAg (Abbott-HBe). 
Serum total haemolytic complement was assayed using sensitised 
sheep red blood cells as previously described26 , C3 and C4 
were measured by single radial immunodiffusion using 
Hyland commercially prepared plates (Immuno-plate IV, 
diagnostics), and circulating immune complexes by the Clq 
binding method27 • 
Rheumatoid factor was assayed by the latex particle 
agglutination method of Singer and Plotz28 , and the sheep 
erythrocyte agglutination test (SCAT) 29 • 
16 
Anti-nuclear antibodies were assayed with fluorescein labelled 
sheep anti-human immunoglobulin (Wellcome Diagnostics) using 
mouse liver as substrate. Anti-DNA antibodies were measured as 
previously described30 using a modification of the method of 
Ginsberg et a131 • 
All biopsies except 1 were performed percutaneously using a 
"Tru-cut" biopsy needle. One patient underwent open renal 
biopsy. Renal biopsy specimens were immediately divided into 3 
parts. One part was fixed in Bouin's fluid, 1 part in 4% s-
collidine buffered glutaraldehyde and the third part snap 
frozen in liquid nitrogen. Sections for light microscopy were 
stained with haematoxylin and eosin, periodic acid Schiff, 
Masson's trichrome and methenamine silver. 
Material for ultrastructural examination was postfixed in 
osmium tetroxide and embedded in Spurr's resin. Sections were 
stained with uranyl acetate and lead citrate and examined with 
a Phillips 201 electron microscope. 
Frozen sections cut at 4 µm were stained by a direct 
immunofluorescence technique using commercially available 
fluorescein isothiocyanate labelled anti-IgG, anti-IgA, anti-
IgM, antifibrin, anti-CJ, anti-Clq and anti-C4 antisera 
(Beringwerke AG Marburg, West Germany). 
Hepatitis B antigens were detected as follows: Frozen sections 
were fixed in acetone. Endogenous peroxidase activity was 
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blocked using hydrogen peroxide. The sections were then 
incubated with goat anti-rabbit IgG or rabbit anti-mouse serum 
to prevent non-specific binding of labelled antibodies. After 
this they were incubated with either rabbit anti HBc or mouse 
anti HBs (Zymed laboratories Inc. San Francisco, U.S.A.) as 
the primary antibody, followed by biotinylated goat anti-
rabbit or rabbit anti-mouse. The binding sites were then shown 
by incubating the specimens with streptavidin peroxidase 
conjugate and staining with buffered amino-ethyl carbazole. 
Haematoxylin was used as a counterstain. 
The renal biopsies were reviewed and scored according to a 
standard protocol (Appendix II). The lesions of membranous 
nephropathy were staged on electron microscopy according to 
the classification of Churg32 • Stage 1 has only a few 
subepithelial deposits overlaid by podocytes. In stage 2 these 
deposits are more numerous and completely encircle the 
capillary wall. Protrusions of basement membrane separate 
these deposits and are seen as "spikes" on silver stains. In 
stage 3 the spikes fuse over the deposits and some begin to 
resolve. In stage 4 the basement membrane is irregularly 
thickened and contains fading remnants of the deposits. Where 
more than 1 stage was present in a biopsy, it was graded 
according to the dominant stage. 
Other glomerular changes were graded as absent, mild, moderate 
or severe. Mesangial hypercellularity was defined as 4 or more 
mesangial cells per mesangial area. 
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The term diffuse is used to describe a lesion or process that 
involves 80% or more of the glomeruli, and focal is used for 
lesions affecting less than 80% of glomeruli. Global lesions 
involve the whole glomerulus and in segmental lesions only a 
portion of the glomerulus is involved, leaving part of the 
glomerulus uninvolved by that particular lesion or process.
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Terms describing race are taken from the hospital 
classification on the patients folder. White is used to 
describe patients of presumed European origin, Black to 
describe those of presumed indigenous African origin, and 
Coloured those of presumed mixed racial origin or Asian 
descent. 
Hypertension was defined as a blood pressure above the 95th 
centile as defined by the second task force on blood pressure 
control in children34 • 
The term asymptomatic proteinuria is used to describe patients 
with plasma albumin levels above 25 g/1 but less than or equal 
to 35 g/1, 2+ or less proteinuria on dipstix or salicyl 
sulfonic acid testing and no oedema. Complete remission is 
defined as a plasma albumin level above 35 g/1, no more than 
trace amounts of proteinuria and no oedema. 
During the trial of interferon therapy proteinuria was 
assessed by calculating the protein/creatinine ratio on a 
single voided specimen of urine35 • The normal range is below 
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2 o mg protein per mmol creatinine and the nephrotic range 




The records of 559 patients with nephrotic syndrome were 
traced. The clinical and/or histopathological diagnoses 
shown in figure 1 and table 1. 
TABLE 1: CAUSES/HISTOLOGICAL TYPES OF NEPHROTIC SYNDROME 
TYPE TOTAL(%) Tested for 
MCNS 242 (43) 175 
Mes Prolif 97 (17) 71 
MGN 92 (16) 81 
Dif Prolif 33 (6) 22 
Crescentic 20 (4) 10 
APSGN* 11 (2) 9 
MCGN 11 (2) 7 
Chronic GN 11 (2) 9 
FSGS 9 (2) 8 
Cong Syphilis * 9 (2) 9 
Miscellaneous 24 (4) 17 
Totals: 559 418 
HBV = Hepatitis B virus antigens. 
* Indicates clinical diagnosis with no biopsy. 
HBV HBV +VE (%) 













MCNS = Minimal change nephrotic syndrome, Mes Prolif = mesangial 
proliferative glomerulonephritis, MGN = membranous glomerulonephritis, Dif 
Prolif = diffuse proliferative glomerulonephritis, Crescentic = crescentic 
glomerulonephritis, APSGN = acute post streptococcal glomerulonephritis, 
MCGN = mesangiocapillary glomerulonephritis, 
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Nephrotic syndrome 
Frequency of causes and HB virus status , 
Cause 
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Mes Prolif GN 
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• p < 0,000001 
Figure 1. 
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Of the 242 patients with a diagnosis of minimal change 
nephrotic syndrome {MCNS), 61 were biopsy proven. There were 
only 12 patients with congenital syphilis. This is the result 
of selection bias, as most patients with congenital syphilis 
are treated in the general paediatric wards or in the neonatal 
units and are not referred to the renal service. Of these, 3 
underwent biopsy (2 membranous and 1 acute diffuse 
proliferative) and the rest were diagnosed on clinical and 
serological grounds. 
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Acute post streptococcal glomerulonephritis with nephrotic 
syndrome was diagnosed in 39 patients. Twenty-eight of these 
underwent renal biopsy which showed acute diffuse 
proliferative glomerulonephritis in all cases, and 11 were 
diagnosed on clinical and serological grounds. 
There were 24 (4%) other patients with a variety of diagnoses. 
Included in this group are 2 patients who, on clinical grounds 
were suspected of having HBV associated nephrotic syndrome 
(NS) , but in whom renal biopsy was not successful. One of 
these patients had a severe bradycardia at induction of 
general anaesthesia for biopsy and the procedure was 
abandoned, and the other biopsy specimen contained no 
glomeruli. These 2 patients have been included in the 
assessment of causes of NS in black patients and the causes of 
secondary NS, but have been excluded from further analysis. 
There were 148 patients who had an identifiable cause of 
nephrotic syndrome (figure 2). In 74 (50%) of these nephrotic 
syndrome was felt to be secondary to HBV infection. 
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Secondary nephrotic syndrome 
Frequency of causes 
Hepat i t is B 74 
Other 12 
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n • 148 
Figure 2 
There were 92 patients with membranous nephropathy. Seventy-
one {87,6%) of the 81 tested were HBV positive. Of those with 
membranous nephropathy and negative HBV tests, 2 had 
congenital syphilis, 2 were felt to have idiopathic membranous 
nephropathy and 1 systemic lupus erythematosus (SLE). Of the 
patients with unknown HBV results, 1 had SLE, 1 cystinuria 
with penicillamine-induced membranous nephropathy, and 1 was 
felt to have idiopathic membranous nephropathy. The records of 
the . remaining 14 patients had been partly destroyed and 
I 
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inadequate information was available to make any further 
diagnosis. 
A total of 102 (24, 4%) of the 418 patients tested for HBV 
infection were positive. The histopathological types seen on 
renal biopsy in these patients is shown in fig 3. Seventy-one 
(69,6%) of these patients had MGN. This distribution is highly 
significant (p < 106) (Chi-squared). Thirteen patients had 
mesangial proliferative GN. HBV infection was significantly 
more frequent in these patients than in those with minimal 
change disease (p < 0,005). 
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n • 102 
Figure 3. 
This distribution causes some difficulty. Firstly, although 
there is an apparently significant increase in HBV carriage in 
patients with mesangial proliferative glomerulonephritis when 
compared with other patients with NS, the HBV positive rate is 
only slightly higher that found in certain sectors of the 
general population36 • Furthermore, the frequency of HBV 
infection in patients with membranous nephropathy is very much 
higher than that in mesangial proliferative disease {p < 10-
11) . . As there seemed to be no clear method of selecting those 
patients { if any) whose disease may have been caused by HBV 
infection, no patients with mesangial proliferative disease 
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have been included for further analysis. However, the 
relationship between HBV infection and mesangial proliferative 
GN merits further study. 
The study group therefore consisted of the 71 patients with 
MGN and 1 patient with MCGN. The patient with MCGN was 
included for 2 reasons. Firstly MCGN has been described in 
association with HBV infection and this relationship seems to 
be generally accepted21 , and secondly HBsAg and HBcAg were 
demonstrated within the immune complexes deposited in the 
glomeruli. In addition, many of our patients with MGN 
associated with HBV have at least some histopathological 
features of MCGN. 
Clinical and demographic data: 
RACE AND SEX: 
The group of 72 study patients was constituted as follows: 




b.) Race: Coloured: 43 (60%) (37 boys, 6 girls) 
Black: 28 (38%) (23 boys, 5 girls) 
White: 1 (1%) (1 girl) 
The frequency of minimal change nephrotic syndrome among Black 
children is known to be considerably lower than in Whites or 
27 
children of Asian origin1 • For this reason, the distribution 
of causes of the nephrotic syndrome in Black children was 
examined. The results are shown in figure 4. 
Nephrotic syndrome in Blacks 
Histological types / Causes 
Mesangial prolif 18 
20% 
Minimal change 17 
19% 




n • 91 
Figure 4. 
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Figure 5 . 
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C.) AGE AT ONSET: 
The distribution of ages at the time of onset is shown in 
figure 5. The ages ranged from 13 months to 164 months ( 13 
years 8 months) The peak incidence is in the 6-7 year age 
group, and the mean age at presentation 79 months. 
0.) GROWTH PARAMETERS 
All patients were routinely weighed and had height 
measurements recorded. The weight used in this assessment was 
the lowest recorded within 6 weeks of presentation to Red 
Cross Children's Hospital. This was done to minimise over-
estimation of weight due to oedema. Diuretic therapy with or 
without intravenous albumin infusions was given to severely 
symptomatic patients. Weight loss during this time averaged 
12,9% (range O - 44%). Eight patients (11%) lost more than 25% 
of their weight at presentation with resolution of oedema. 
The anthropometric data are summarised in the accompanying 
figures. There is a striking degree of stunting in these 
patients, as shown in figure 7. Weight for age and weight for 
height may be overestimated because these patients seldom, if 
ever, lose all their oedema within 6 weeks. 
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Figure 8. 
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E.) CLINICAL SIGNS 
All patients presented with heavy proteinuria and the clinical 
features of nephrotic syndrome. The clinical signs present are 
summarised in table 2. 
TABLE 2: CLINICAL SIGNS AT PRESENTATION. 
SIGN NUMBER (PERCENT) 
Oedema 72 (100) 
Proteinuria 72 (100) 
Ascites 51 (71) 
Micro-haematuria 51 (71) 
Hepatomegaly * 29 ( 40) 
Pleural effusion 24 (33) 
Hypertension 19 (26) 
Macro-haematuria 15 (21) 
Splenomegaly ** 8 (11) 
* Hepatomegaly = liver palpable more than 2 cm below the costal margin in 
the mid-clavicular line. 
** Splenomegaly = palpable spleen. 
OTHER DISEASES: 
Thirteen patients (18%) had tuberculosis (TB) at presentation. 
Eleven had pulmonary TB, 1 had abdominal TB, and 1 had 
tuberculous meningitis. Eight of the 13 have entered 
remission, an average of 3 2 months after onset of symptoms. 
Two defaulted after 13 and 38 months of follow-up, and 3 are 
still followed after 30, 49 and 114 months. The latter patient 
developed end stage renal failure. 
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Five patients had acute pneumonia at presentation, 3 had 
asthma, 2 had upper respiratory tract infections, 1 had 
Staphylococcal septicaemia and 1 had severe Herpes Simplex 
Virus stoma ti tis. One patient was from the Worcester School 
for the Deaf, and 1 had a congenital spinal cord defect 




The results of urine microscopy are shown in table 3. 
II 
TABLE 3: URINE MICROSCOPY. 
FEATURE NUMBER POSITIVE 
Red blood cells: 66 














Microscopy for red and white blood cells was considered positive if 
there 




Plasma chemistry profile: 
The serum biochemistry results are summarised in table 4. 
II 
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ALT= alanine aminotransferase, Clcreat = corrected creatinine clearance, 
Calculated GFR = glomerular filtration rate calculated according to the 
formula GFR = height (cm) x 38 / serum creatinine (µmol/1), Selectivity= 
proteinuria selectivity index. 
All patients had decreased serum albumin levels. Two patients 
had initial plasma albumin levels above 25 g/1; in both the 
level subsequently fell below this. Total protein levels were 
similarly decreased in most patients. 
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Using formal endogenous creatinine clearance studies, 15 of 57 
(26%) patients had initial creatinine clearances of less than 
80 ml/min/1,73m2 . Using the other method, 16 of 71 (23%) had 
values less than 80. Comparison of the two methods using 
linear regression analysis in the 50 patients in whom both 
were available showed only a fair correlation (r = 0,59). 
Of the 16 patients with a calculated GFR of less than 80 
ml/min/1, 73m2 at presentation, only 4 had results below this 
level at the last follow-up. In 1 patient the value remained 
unchanged and in 1 it rose from 32 to 47 ml/min/1,73m
2. In the 
other 2 cases the calculated GFR fell; in 1 case from 36 too, 
and in the other 79 to 54. Eight other patients had a 
calculated GFR of less than 80 at last follow-up. 
Proteinuria is expressed as mg/m
2/hour. The International 
Study of Kidney Disease in Children (ISKDC) definition of 
nephrotic syndrome is a protein excretion rate of more than 40 
mg/m2/hour22 • One patient had a measured protein excretion 
rate below this (26 mg/m2/hour). As she had a plasma albumin 
of 19 g/1 and plasma cholesterol of 6,60 mmol/1 it seems 
likely that this was an under-collection. 
Proteinuria was highly selective (proteinuria selectivity 
index< 10%) in 10 patients (29%) and poorly selective (index 
> 20%) in 8 (24%). Most (47%) had moderately selective 
proteinuria. 
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Proteinuria selectivity index 
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Figure 9. 
Serum alanine aminotransferase (ALT) levels are summarised in 
table 4. While 43 of 59 (73%) had levels above 30 U/ 1 (the 
upper limit of normal in our laboratory), in most patients the 
elevation remained modest and tended to fluctuate during the 
course of the disease. No patient was clinically jaundiced and 
only 1 had a history of jaundice, 4 months previously. None 
had symptomatic liver disease. T.hree patients underwent liver 




These are summarised in table 5. Sixteen patients had 
normocytic anaemias, usually mild (the lowest haemoglobin was 
9,5 g/dl). Six patients had microcytic anaemias and a further 
4 had microcytosis with haemoglobin levels within the normal 
range. 
Most patients had normal leucocyte counts. The range was from 
3,6 x 109 /1 in the patient with hypersplenism to 31,8 x 109 /1 
in a patient with peritonitis at presentation. Differential 
counts were either normal or showed an increase in neutrophils 
in patients with infection. 
Platelet counts tended to be elevated; 24 {36%) of 66 patients 
in whom counts were recorded had more than 450 x 109 platelets 
per litre. Only one patient had a low platelet count, 
secondary to hypersplenism. 
II 
TABLE 5: HAEMATOLOGICAL DATA 
II 
VARIABLE (n) AVERAGE RANGE S.D. 
Haemoglobin (g/dl) (71) 11,7 7,8 - 15,2 1,5 
MeV (fl) (64) 81,0 66 - 91 5,5 
wee (x109 / 1) (70) 13,2 3,6 - 31,8 5,4 
Platelets {xl09 /1) (65) 412 105 - 971 178,0 
Mev = Mean cell volume; wee= White blood cell count. 
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Microbiology: 
URINARY TRACT INFECTION: 
All patients had urine cultures at presentation. Five (4 
males) were positive, with a pure growth of more than 100 000 
organisms per ml. Two grew Klebsiella species, 2 E. coli, and 
1 a Proteus species. Further investigations for structural 
abnormalities predisposing to infection were negative in all 5 
cases. 
STREPTOCOCCAL INFECTION: 
Fifty patients had skin and/or throat swabs taken for possible 
Lancefield group A beta-haemolytic streptococcal infection. 
Eight throat swabs were positive. None of the skin swabs were 
positive. 
SEROLOGICAL TESTS FOR STREPTOCOCCAL INFECTION: 
Anti-streptolysin O titre (ASOT):n = 69 
Anti-DNAse B: 
>200 I.U.: 14 (20%) 
µ200 I.U.: 55 (80%) 
n = 23 
>200 I.U.: 8 (35%) 
µ200 I.U.: 14 (65%) 
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SEROLOGICAL TESTS FOR SYPHILIS: 
Routine tests for syphilis (rapid plasma reagin (RPR) or the 
venereal disease research laboratory (VDRL)) slide test were 
done on 70 patients. All except one were negative. The 
exception was a child of 34 months who had previously been 
treated with a 10 day course of procaine penicillin for 
congenital syphilis diagnosed at 6 days of age. The Treponema 
pallidum haemaglutination assay remained positive despite a 
further course of penicillin therapy. His nephrotic syndrome 
continued for 42 months. He became asymptomatic within 5 
months of clearing the HBeAg from his blood, and had complete 
resolution with no residual urinary abnormalities 17 months 
later. 
TESTS FOR HEPATITIS B VIRUS INFECTION: 
Prior to about 1980 the connection between HBV infection and 
renal disease was not generally appreciated, and HBV markers 
were not routinely sought in patients with nephrotic syndrome. 
HBeAg tests became available only some time after HBsAg tests 
had been in use (1976). In this series, 1 patient with well 
documented membranous nephropathy was tested only after his 
renal disease had undergone complete remission. His serum was 
positive for surface antibody and e antibody, but negative for 
all HBV antigens. A further 9 patients were first tested for 
HBeAg after resolution of the disease and were negative at 
that time with positive tests for anti HBe, but had 
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persistently positive tests for HBsAg, both earlier, during 
the active phase of disease and after remission. 
No HBeAg results were available in 5 patients. All but 1 had 
presented before 1976. Fifty-seven patients had tests for 
HBeAg while the disease was active. Fifty-six were positive. 
The single patient who was persistently negative for HBeAg 
became asymptomatic with mild proteinuria only 24 months after 
presentation and initial testing. 
At the time of the last clinic visit, 39 patients were HBeAg 
negative, and 33 remained HBeAg positive. Of the 39 patients 
who were HBeAg negative, 34 were in complete remission and 5 
had asymptomatic proteinuria only. Only 7 of the 72 patients 
had cleared the surf ace antigen from the serum. The average 
interval between the last positive test for HBeAg and the 
first negative test was 8,3 months (range 1 - 23 months). This 
interval is influenced by the test interval rather than time 
taken for seroconversion. 
Twenty patients had repeated HBV antigen tests during the 
course of their renal disease and after remission. The average 
interval from the first negative test for HBeAg to complete 
remission was 5 months (range: remission 24 months before 
seroconversion to 31 months after seroconversion). 
Four patients were in remission but still had positive tests 
for HBeAg. Two of these were last tested for HBeAg on the same 
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day they were first found to be in remission. The other 2 were 
last tested 9 and 33 months after complete remission of 
proteinuria. 
Hepatitis B serological studies were done on 39 mothers. Of 
these, 15 (38%) had evidence of present or past HBV infection. 
Immunological activation and auto-antibodies: 
The results of assays for serum markers of immunologic 
activation are shown in figures 10 to 12 and summarised in 
table 6. 
Most patients had some depression of serum complement 
components, although some had elevated levels. Slightly more 
patients had low levels of the 3rd (CJ) than 4th (C4) 
components (67% versus 47%), indicating probable alternate 
pathway activation in those patients. 
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Serum total complement 
Units/ml 
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Figure 10. 
45 
Serum levels of third 
component of complement 
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Figure 11. 
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Serum levels of fourth 
component of complement 
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Figure 12. 
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Of the 29 patients in whom circulating immune complexes were 
assayed, all but 6 were within the normal range (< 7% Clq 
binding), and only 3 had levels above 15% (68,3; 79 and 
87,1%). 
Rheumatoid factor was assayed in 32 patients. The SCAT was 
negative in 30 cases. The remaining 2 had positive tests to 
titres of 16 and 32. Latex tests were negative in 29 patients, 
and .the remaining 3 had positive titres of 40, 80 and 320. 
Titres for . both tests were positive in only one patient, who 
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had a SCAT of 32 and latex of 320. This patient had no 
evidence of rheumatoid arthritis, was asymptomatic within 13 
months, and in complete remission within 25 months. Remission 
coincided with clearing thee antigen from her circulation. 
Antinuclear factor (ANF) was measured in 58 patients, and was 
negative in 54. Of the positive results, 2 had titres of 10, 1 
of 20 and 1 of 2500. None of these patients had any evidence 
of systemic lupus erythematosus (SLE). 
Anti-DNA antibodies were measured in 44 patients, and were 
within the normal range of O - 10 µg DNA bound per ml of serum 
in 27. The distribution of elevated levels was as follows: 11 
µg/ml: 6 patients; 13 µg/ml: 1 patient; 15 µg/ml: 2 patients; 
and 1 patient each had levels of 18, 20, 21, 23, 33, 34, 37 
and 91 µg/ml. None had other features of SLE. 
The patient with an ANF titre of 2500 had an anti-DNA antibody 
level of 5 µg/ml, and the patient with anti-DNA antibodies of 
91 µg/ml had a negative test for ANF. 
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Total complement: (66) 
(160 - 220 U/ml) 
C3: (67) 
(115 -150 mg/dl) 
C4: (55) 
(20 - 45 mg/dl) 








55 - 286 58,5 
16 - 340 56,7 
6 - 61 15,1 
1,1 - 87,1 * 
C3 = third component of complement, C4 = fourth component of complement, C.I.C. = circulating immune complexes. 
*c.I.C median value= 2,9; geometric mean= 4,4. 
Radiological features: 
Prior to 1981 all patients underwent intra-venous pyelography 
(IVP). Since that time ultrasound has largely replaced IVP. As 
all X-ray films are destroyed after 4 years only 2 sets of 
films were available for examination. One patient had a duplex 
system on the left. Apart from large kidneys (+2 - +3 stndard 
deviations) there were no other abnormalities. Those cases 
where the films were not available for examination were 
excluded from further analysis. 
Renal ultrasound scans were available on 18 patients. In all 
except 2 cases the kidneys were of increased echogenici ty. 
Renal length measured by ultrasound imaging was available for 
14 patients (28 kidneys). The results are shown in figures 13 
and 14. Fifteen (54%) of the kidneys were larger than the 95% 
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confidence level for the upper limit of normal 
37
, and only 1 
was below the mean length for patient height. 
Sonographically measured kidney length: 
Right kidney 
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Figure 13. 
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Sonographically measured kidney length: 
Left kidney , 
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Clinical course of the disease: 
FOLLOW-UP 
The 72 patients were followed for an average of 46,4 months, 
with a range of 2 to 139 months (median 41 months) . Eleven 
patients were followed for less than 12 months. Twelve 
patients (16%) defaulted after a varying follow-up period and 
could not be traced. Of these 11 had active nephrotic syndrome 
when last seen and 1 had asymptomatic proteinuria. The 
duration of follow-up among the defaulters with nephrotic 
syndrome when last seen ranged from 2 to 38 months (mean 14,5 
months, median 13 months). The patient who defaulted with 
asymptomatic proteinuria did so after 89 months. One patient 
died in a motor vehicle accident a few days after his last 
Renal Clinic visit, at which time he was asymptomatic but had 
mild persistent proteinuria. The follow-up status of all 
patients at their last clinic visit are shown in table 7. 
'' 
TABLE 7: PROTEINURIA AT LAST VISIT II 
STATUS NUMBER (PERCENT) 
Remission: 38 (53) 
Nephrotic: 25 ( 35) 
Asymptomatic proteinuria: 7 (10) 
End-stage renal failure: 1 (1) 
Post renal transplant: 1 (1) 
The mean interval from onset of symptoms to becoming 
asymptomatic in the 45 patients was 22,9 months, with a range 
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from 2 to 80 months. The median interval from onset to the 
asymptomatic state was 18,0 months. 
The average duration of proteinuria in the 38 patients in 
complete remission was 30, O months, with a range of 5 to 95 
months, and median of 27 months. Of those patients who went 
into remission, all but 5 did so in under 40 months. The 
average interval from becoming asymptomatic to complete 
remission was 10 months (range o to 32 months, median 8, 5 
months). 
Twenty-six patients still had active nephrotic syndrome when 
last seen. The average duration of symptoms in these patients 
was 25,2 months, with a range of 2 to 82 months. Of these 
patients, 7 have had symptomatic disease for more than 40 
months. 
Figure 15 shows the follow-up status of all patients. The 
shaded bars represent the time of entering remission in those 
patients who did so. The hatched bars represent the most 
recent clinic visit by those patients not yet in complete 
remission. 
The 38 patients who went into complete remission were followed 
up for an average of 27 months after remission (range o - 133 
months, median 22 months). None had a relapse of nephrotic 
syndrome. 
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The cumulative probability of remission (from life table 
analysis) is shown in figure 16. A 70% 5 year remission rate 
was observed. 
Duration of nephropathy 
Time to remission/ duration of follow-up 
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Fi gure 15. 
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Cumulative probability of remission 
or asymptomatic proteinuria 
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Figure 16. 
RENAL FUNCTION: 
In most cases renal function was well preserved. The average 
change in calculated GFR was +18,3%. Nine patients had a 
decline in GFR of more than 25% between presentation and last 
follow-up visit. Thirteen had a calculated GFR of less than 80 , 
ml/min/1, 73 m2 at the last visit, of which 5 were under 50 
ml/min/1,73 m2 . Two patients (2,8% of the total or 3,3% of 
those followed for mor·e than 12 months) progressed to end-
stage renal failure; 1 within 12 months and the other after 




Peritonitis: There were 16 episodes of peritonitis in 8 
children. Two patients had 2 episodes each and one had no 
fewer than 6 episodes. In 9 episodes Streptococcus pneumoniae 
was the responsible organism. In 2 cases there was no 
bacterial growth obtained although Gram stain showed numerous 
pus cells. In the remaining 6 cases peritoneal aspirate was 
either not cultured or the results could not be traced. Since 
it became available, all patients with nephrotic syndrome have 
been immunised against pneumococcal infection (Pneumovax, 
Logos). 
Cellulitis: Two patients had episodes of cellulitis. One 
patient had a single episode and the other recurrent group A 
beta-haemolytic Streptococcal cellulitis. 
Other 
tract 
inf actions: Four patients had 5 
infection during the course of 
episodes of urinary 
their illness. Two 
patients had measles and 3 had chickenpox without major 
complications. 
2. Thrombosis: 
Three patients suffered 4 thrombotic complications. One 
patient had a left middle cerebral artery thrombosis with 
resultant right sided hemiplegia. Extensive investigations 
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found no vascular or other haematological abnormality. One 
patient had a thrombosis of his right popliteal artery which 
required embolectomy, and the third patient had 2 separate 
episodes of deep venous thrombosis involving each leg in turn. 
3. Renal Failure: 
There were no episodes of acute renal failure. Eight patients 
at last follow-up had mild renal impairment (GFR < 80 but> 50 
ml/min/1,73m2 ) as assessed by the calculated GFR. A further 5 
patients had a GFR of less than 50 ml/min/1, 73m
2 • Two had 
severe renal failure, with a GFR of 11 or less. One patient 
developed end stage renal failure within 1 year of onset of 
symptoms. He was initially maintained on chronic ambulatory 
peritoneal dialysis and given a course of Interferon alpha 2b 
( see below) . He subsequently received a cadaver donor renal 
graft, and has done well. Seven months after the transplant he 
is normotensive, has no proteinuria, and maintains a serum 
creatinine concentration of approximately 70 µmol/1. 
One further patient had slowly declining renal function. Ten 
years after onset of his disease he now has a GFR of 11 
ml/min/1,73m2 . 
4. Hypertension: 
One child had convulsions due to hypertensive encephalopathy 
while receiving steroid therapy. Although 19 patients were 
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hypertensive at presentation, only 10 had hypertension at the 
last clinic visit. 
5. Other: 
one patient developed necrosis of part of the prepuce 
secondary to severe oedema of the genitalia. 
THERAPY: 
Fifty-eight of the 73 patients received only supportive 
treatment. Ten received steroids for 4-8 weeks, 2 received 
steroids and cyclophosphamide and 3 received interferon alpha 
2b after steroid withdrawal. 
1. Steroids: 
Of the 10 patients given steroids, 6 had gone into remission 
by the time of their last visit. In none of these cases did 
remission occur during therapy, and only 1 went into remission 
within 6 months of steroid treatment. Two had defaulted while 
still having nephrotic syndrome at 22 and 15 months after 
onset. One had asymptomatic proteinuria after 45 months and a 
4th still had nephrotic syndrome after 30 months. The 
remaining patients went into remission an average of 34, 5 
months after onset (range 5-90 months). This is similar to 
those patients who received no specific therapy (31 patients 
in full remission, mean duration of nephrotic syndrome 29, 6 
months, range 6-95 months), (p > 0,5). Steroid therapy was 
complicated in 1 patient 
hypertensive encephalopathy. 
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by severe hypertension and 
2. Steroids and cyclophosphamide: 
Two patients were given steroids and cyclophosphamide in 
combination for 8 and 12 weeks before the relationship between 
HBV infection and renal disease was recognised. They went into 
remission at 6 and 38 months after onset respectively. One of 
these patients had alopecia, leucopaenia and thrombocytopaenia 
as complications of therapy. 
3. Interferon: 
In 1989, after several promising reports on the use of 
interferon in patients with HBV related chronic liver 
disease38- 40 , it was decided to undertake a limited, 
uncontrolled trial of interferon therapy in 3 patients with 
particularly severe HBV related nephropathy. It was hoped that 
remission could be induced by eliminating the virus or at 
least the hepatitis B e antigen. Consent for this study was 
obtained from the Medicines Control Council and from the 
parents of the children concerned. 
The proposed protocol was as follows: An initial 3 week period 
of steroid therapy (prednisolone 2 mg/kg/day to a maximum of 
60 mg/day for the first week, half this dose during the second 
week and 1 quarter for the third week) . Interferon alpha 2b 
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(Intron A, Scherag) therapy was started in a dose of 7, 5 
Mu/m2 /dose (to a maximum of lOMu/dose) given by subcutaneous 
injection 3 times per week for 12 weeks. Blood was taken at 
the start of steroid therapy, at the start of interferon 
therapy, and at intervals of 4 weeks thereafter for full blood 
count (FBC) and full serum biochemical analysis. Random urine 
specimens were collected at the same times for urine protein: 
creatinine ratios and proteinuria selectivity index. In 
addition any further investigations were performed as dictated 
by clinical assessment from time to time. 
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Presented in March 1988 with nephrotic syndrome 
and HBV infection. Renal biopsy showed grade 
III membranous nephropathy. Between March 1988 
and October 1989 he had required 7 hospital 









Creatinine clearance fell from 119 ml/min/ 1, 73 
m2 at diagnosis to 22 ml/min/1,73m2 at the 












Developed umbilical sepsis at 3 weeks of age. 
This resulted in portal vein thrombosis. 
Between September 1977 and March 1983 she had 
numerous admissions for bleeding oesophageal 
varices, and received over 100 units of blood 
both in Cape Town and Zimbabwe. Her oesophageal 
varices were injected on numerous occasions. A 
mesocaval shunt and subsequently a Le Veen 
shunt both failed to relieve either the ascites 
or the portal vein pressure. Serum albumin at 
that time was normal. The Le Veen shunt was 
removed in May 1988 as the tip had migrated out 
of the vein. 
In April 1986 she developed haematuria and 
nephrotic syndrome. HBV antigens were checked 
for the first time and HBsAg and HBeAg were 
both positive. Renal biopsy showed 
mesangiocapillary glomerulonephritis. Her 
course was complicated by bilateral deep vein 
thrombosis of the calves, 6 episodes of 
peritonitis and several episodes of cellulitis. 













Presented in March 1988 with nephrotic 
syndrome, impaired renal function and positive 
tests for HBsAg and HBeAg. Renal biopsy showed 
membranous nephropathy with focal areas of 
sclerosis and some crescents. 
His renal function deteriorated and in March 
1989 he was started on Continuous Ambulatory 
Peritoneal Dialysis (CAPO). In his case 
interferon therapy was given in an attempt to 
reduce the risk of cross infection in the 
transplant unit and to prevent the possible 
recurrence of disease in a transplanted kidney. 
Patient 49 developed an acute exacerbation of her hypertension 
and of dyspepsia related to severe reflux oesophagi tis. For 
these reasons her steroid course was shortened to 5 days for 
each dose. 
B) INTERFERON: 
All 3 patients experienced 'flu-like symptoms. These were most 
severe in the oldest patient and trivial in the youngest. 
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Patients 49 and 64 had fevers of up to 38,5°C after the first 
3 injections. During the second week the highest temperature 
recorded was 38°C, and thereafter there was no elevation of 
temperature. Patient 56 had a fever of up to 37,5°C during the 
first week only. The 2 older patients complained of headaches 




starting 10 days 
of vesicles mainly on the 
after the first interferon 
injection. Fluid form the vesicles was negative for viral and 
bacterial culture. Because of this rash the dose of interferon 
was reduced to 5 Mu/ dose after 3 weeks and the course of 
treatment prolonged to 16 weeks. 
There were no haematological or biochemical complications. 
RESULTS: 
A) HEPATITIS B MARKERS: 
All 3 patients were HBsAg and HBeAg positive, and anti-HBsAg 
anti-HBeAg negative at the start of treatment. Patient 64 
seroconverted to anti-HBe antibody positive after 4 weeks of 
interferon therapy and after 12 weeks he was negative for 
HBeAg but remained HBsAg positive. The other 2 patients 
remained both surface and e antigen positive. 
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B) PROTEINURIA: 
A decline in proteinuria occurred in patients 49 and 64. Both 
patients had urinary protein/creatinine ratios of well over 
800 mg/mmol at the start of therapy, and both fell to below 
100 mg/mmol. There was no change in patient 56. The results 
are shown in figures 17 and 18. Patient 64 absconded 4 weeks 
after completing interferon therapy. Patient 49 had a 
temporary improvement in proteinuria which lasted 20 weeks 
before relapsing to former levels. 
C) SERUM ALBUMIN: 
Together with the decline in proteinuria there was a rise in 
serum albumin from 16 g/1 to 27 g/1 in patient 64 and from 22 
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Serum albumin & proteinuria, patient 64 
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Figure 18. 
D) RENAL FUNCTION: 
Patient 64 absconded before formal renal function tests could 
be performed, but his serum urea fell from 11,7 nunol/1 at the 
s t art of therapy to 5,1 nunol/1 4 weeks after completing 
treatment, and his creatinine fell from 125 µmol/1 to 93 
µmol/1 (estimated GFR 53 ml/min/1,73 m2 ). There was no change 
i n the glomerular filtration function of the other 2 patients. 
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HISTOPATHOLOGICAL DATA: 
Seventy-five renal biopsies were performed on 71 patients. One 
patient was biopsied in Durban, and his biopsy was not 
available for review. One patient had 2 and 1 had 3 biopsies. 
The median interval from onset of symptoms to first renal 
biopsy was 2 months (range O, 5 to 50 months, average 3, 8 
months). 
Seventy-one patients were classified as having membranous 
nephropathy and 1 had mesangiocapillary glomerulonephritis 




Glomerular basement membrane: 
Abnormalities of the glomerular basement membrane (GBM) were 
the most striking and consistent feature on light microscopy, 
seen in all 71 biopsies examined. The GBM was diffusely 
thickened in all cases. Thickening was global in 63 {89%) and 
segmental in 8 {11%). The degree of thickening was 
subjectively graded as mild in 4 cases {6%), moderate in 43 
{60%), and severe in 24 {34%). 
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"Spikes" (protrusions of GBM material on the epithelial aspect 
seen on silver stained sections) were present in 69 (97%) of 
the 71 biopsies. (See figure 19.) 
Splitting of the GBM seen with methenamine silver stains was 
present to some degree in 42 (59%) of biopsies. In 8 patients 
it was particularly pronounced, giving a light microscopic 
appearance of mesangiocapillary glomerulonephritis. (See 
figures 21 and 25.) One biopsy (patient 49) was classified as 
mesangiocapillary glomerulonephritis on the basis of absence 
of significant subepithelial immune complex deposits and 
massive subendothelial deposits seen on electron microscopy. 
(See figures 22 and 26.) The GBM features on light microscopy 
are summarised in table 8. 
Of the 70 biopsies classified as membranous, 3 were stage 1, 
34 were stage 2, 28 were stage 3 and 5 were stage 4. There was 
no correlation between the interval from onset of symptoms to 
time of biopsy and staging of membranous nephropathy, the 
degree of splitting of the GBM seen on light microscopy, or 
the degree of mesangial interposi tioning between the GBM and 
endothelium seen on electron microscopy. 
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TABLE 8: GBK ABNORMALITIES ON LIGHT MICROSCOPY 
DISTRIBUTION (%AGE of BIOPSIES) 
FEATURE F&S F&G D&S D&G 
Thickening: 0 0 8 (11) 63 (89) 
Spikes: 11 (15) 1 (1) 28 (39) 29 ( 41) 
Splitting: 16 (23) 0 18 (25) 8 (11) 
Chaining: 18 (25) 0 24 (34) 14 (20) 
F&S = focal and segmental; F&G = focal and global; D&S = diffuse and 
segmental; D&G = diffuse and global. 
Capillaries: 
Narrowing of the glomerular capillary lumen was present in 38 
(54%) of biopsies. This was assessed as mild in 13 (18%), 
moderate in 18 (25%) and severe in 7 (10%). Endothelial cell 
proliferation was not observed. 
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Figure 19. Methenamine silver stain showing pink subepithelial 
deposits and black "spikes". (Patient 67) 
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Figure 20. Masson's trichrome stain. The GBM is markedly 
in the 
thickened. Red immune complexes are 




Figure 21. Methenamine silver stain showing extensive 
splitting of the basement membrane. "Spikes" are visible in a 
few areas. (Patient 66) 
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Figure 22. Methenamine silver stain of biopsy from patient 49 
with mesangiocapillary glomerulonephritis showing mesangial 
proliferation and extensive splitting of the basement 
membrane. (Same biopsy as figure 25.) 
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Mesangium: 
Mesangial abnormalities were present in all biopsies examined. 
All showed an increase in mesangial matrix, which was diffuse 
in 62 (87%) and segmental in 70 (99%). The increase in 
mesangium gave a lobulated appearance to the glomeruli in 7 
biopsies. 
Mesangial cellular proliferation (4 or more cells per 
mesangial area) was present in 66 cases (93%). In 47 (71%) it 
was diffuse and in 17 (25%) focal. 
Other features: 
A polymorphonuclear leucocyte infiltrate (5 or more cells per 
glomerulus) was present in 4 biopsies (6%). 
Focal glomerular sclerosis was present in 10 cases (14%). This 
was segmental in 6 (8%) and global in 4 (6%). The percentage 
of glomeruli involved ranged from 5 - 55%, but 6 had less than 
10% of glomeruli involved. Necrosis of glomeruli was not 
observed. 
Cellular crescents were present in 5 cases. One patient had 
circumferential crescents in 35% of 20 glomeruli. The others 
all had small crescents affecting less than 30% of glomeruli. 
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Bowman's capsule was normal in 18 cases (25%). Adhesions were 
present in 53 cases (75%), 6 (8%) had mild or moderate 
fibrosis and 20 (28%) showed thickening of the basement 
membrane. 
Sections treated with Masson's trichrome stain were available 
in 69 patients. These showed proteinacious deposits in the 
subepithelial region in 55 (80%) and in the mesangium in 45 
(65%). Only 1 patient (with mesangiocapillary 
glomerulonephritis) 
position. 
had deposits in the subendothelial 
Tubules and interstitium: 
The histology of the tubules in summarised in table 9. 
TABLE 9: HISTOLOGY OF THE RENAL TUBULES 
FEATURE: NUMBER (PERCENT) 
Normal 55 (77) 
Basement membrane 
thickening 12 (17) 
Atrophy 11 (15) 
Dilatation 4 (6) 
Casts 3 (4) 
Necrosis 0 (0) 
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INTERSTITIUM: 
The interstitium was entirely normal in 40 cases (56%). In 24 
there was an interstitial infiltrate of lymphocytes and plasma 
cells. This was subjectively characterised as scant in 12, 
moderate in 8 and heavy in 5. In 2 cases the lymphocytes 
formed lymphoid aggregates and in 1 the infiltrate was 
confined to the perivascular region. 
Interstitial fibrosis was present in 9 biopsies. It was mild 
and focal in 7 cases and more diffuse in 2. Interstitial foam 
cells were present in 6 cases. 
BLOOD VESSELS: 
The blood vessels were normal in 66 biopsies (93%) . In the 
remaining 5 there was mild medial proliferation. None of these 
patients was hypertensive at presentation. 
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Immunofluorescence: 
The results of inununofluorescence studies were taken from the 
typed pathology reports as there was no way of repeating the 
studies without fresh, frozen biopsy material. Results were 
available in 65 patients. In all cases where inununoglobulins 
or complement components were demonstrated by 
inununofluorescence, they were deposited in a granular fashion. 
The results are summarised in tables 10-16. 
One biopsy (patient 7 2) was tested for rheumatoid factor by 
direct inununofluorescence and found to be negative. This 
biopsy was positive for HBcAg and HBsAg. 





































TABLE 12: IMMUNOFLUORESCENCE: IgA DEPOSITS (n = 65) 
GRADE MESANGIUM CAPILLARY 
None 35 (54%) 25 (38%) 
Light 17 (26%) 24 (37%) 
Moderate 11 (17%) 12 (18%) 
Heavy 2 (3%) 4 (6%) 
TABLE 13: IMMUNOFLUORESCENCE: Cl (n = 63) 
GRADE MESANGIUM CAPILLARY 
None 15 (24%) 6 (10%) 
Light 12 (20%) 13 (21%) 
Moderate 16 (25%) 25 (40%) 
Heavy 20 (32%) 19 (30%) 
TABLE 14: IMMUNOFLUORESCENCE: C3 DEPOSITS (n = 65) 
GRADE MESANGIUM CAPILLARY 
None 14 (22%) 3 (5%) 
Light 6 (9%) 6 (9%) 
Moderate 18 (28%) 26 (40%) 
Heavy 26 (40%) 29 (45%) 
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TABLE 15: IMMUNOFLUORESCENCE: C4 DEPOSITS (n = 58) 
GRADE MESANGIUM CAPILLARY 
None 21 (36%) 11 (19%) 
Light 11 (19%) 16 (28%) 
Moderate 16 (28%) 22 (38%) 
Heavy 12 (21%) 9 (16%) 
TABLE 16: IMMUNOFLUORESCENCE: FIBRIN DEPOSITS (n = 63) 
GRADE MESANGIUM CAPILLARY 
NONE 11 (17%) 8 (13%) 
LIGHT 18 (29%) 19 (30%) 
MODERATE 25 (40%) 25 ( 40%) 
HEAVY 9 (14%) 11 (17%) 
Hepatitis B antigens: 
Twenty-four patients were tested for deposits of HBsAg in the 
glomeruli and 22 were tested for HBcAg. The results are shown 
in table 17. 








15 ( 63) 
16 (73) 
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Eleven biopsies were positive for both HBsAg and HBcAg and 3 were negative for both. Core antigen alone was positive in 6 and surf ace antigen alone in 2. In a further 2 cases only surface antigen was tested: both were positive. 
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Figure 23. Positive staining for HBcAg in subepithelial immune complexes. (Patient 66: same biopsy as figure 21.) 
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Electron microscopy: 
Electron micrographs were available from 68 of the 71 initial 
biopsies. 
GLOMERULAR BASEMENT MEMBRANE: 
The glomerular basement membrane was abnormal in all cases. 
The abnormalities were classified as thickening, reduplication 
(formation of new basement membrane between the epithelial 
cells and sub-epithelial immune complex deposits) and 
mesangial interpositioning between the GBM and endothelial 
cells. The frequency and severity of these abnormalities is 
shown in table 18. 
TABLE 18: GBM ABNORMALITIES ON ELECTRON MICROSCOPY 
ABNORMALITY GRADE NUMBER (%) 
Thickening: None 
Mild 3 (4) 
Moderate 23 (34) 
Severe 33 (49) 
Reduplication: None 23 (34) 
Mild 23 (34) 
Moderate 20 (29) 
Severe 2 (3) 
Mesangial 
Interpositioning: None 28 ( 41) 
Mild 15 (22) 
Moderate 11 (16) 
Severe 12 (18) 
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ELECTRON-DENSE DEPOSITS: 
Electron-dense deposits were found in all biopsies examined. 
All had subepithelial deposits. In 10 cases some of these 
deposits resembled "humps" as seen in diffuse endocapillary 
proliferative glomerulonephritis41 • Of the 4 patients with 
subendothelial deposits, 2 had only scanty deposits and 1 each 
had moderate and heavy deposits. The distribution of the 
deposits is shown in table 19. 
TUBULO-RETICULAR BODIES: 
These were seen within the endothelial cells in 29 of the 68 
(43%) cases reviewed. In this study only existing electron 
micrographs were used and the sections themselves were not re-
examined. In a previous study involving some of the patients 
included in this study, as well as biopsy specimens from 
Cecilia Makiwane Hospital in Ciskei, Mills and Emms were able 
to identify these structures in all cases of hepatitis B 
associated nephropathy examined42 • 
II 
TABLE 19: ELECTRON-DENSE DEPOSITS II 
SITE NUMBER POSITIVE PERCENT 
Subepithelial 68 100 
Intramembranous 54 79 
Subendothelial 4 6 
Mesangial 63 93 
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Figure 24. Electron micrograph showing subepithelial deposits 
separated by "spikes" of GBM. (Patient 67: same biopsy as 
figure 19.) 
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Figure 25. Electron micrograph showing subepithelial immune 
complexes and spikes. There are also 





Figure 26. Electron micrograph showing massive supendothelial 
immune complex deposits. (Patient 49: same biopsy as figure 
22.) 
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Figure 27. Electron micrograph showing tubuloreticular bodies 
within the cytoplasm of an endothelial cell to the right of 
centre. Fading subepithelial immune complex deposits are 
visible at the left of the picture. 
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summary: 
In summary, the typical biopsy features were: 
1. Membranous nephropathy with an associated increase in 
mesangial cells and matrix 
2. Heavy deposition of IgG and C3 in a granular pattern 
along the GBM and in the mesangium. 
3. Extensive immune complex deposition in the subepithelial 
and mesangial areas. 
4. Variable degrees of mesangial cytoplasmic 
interposi tioning between the GBM and endothelial cells. 
This results in laying down of new GBM material giving an 
appearance similar to MCGN. 




Follow-up biopsies were performed in patients 22 (2 biopsies), 
42 (3 biopsies) and 56 (3 biopsies). 
Patient 22 had biopsies performed 4 and 18 months after onset 
of symptoms. The first biopsy showed stage 3 membranous 
nephropathy and the second stage 4. Both biopsies showed only 
mild mesangial changes and no other features of note. He 
became negative for HBeAg after 65 months, and asymptomatic 
after 78 months. Heis still followed and remains asymptomatic 
and normotensi ve 114 months after onset of his illness. He 
remains HBsAg positive and has persistent mild proteinuria 
with normal renal function (calculated GFR 118 ml/min/1,73m2 ) 
and normal blood pressure. 
Patient 42 had 3 biopsies 3, 35 and 63 months after onset of 
symptoms. The first biopsy showed stage 2 membranous 
nephropathy with a mild increase in mesangial matrix and 
cells. No evidence of basement membrane splitting or mesangial 
interpositioning was seen on either the silver stains or on 
electron microscopy. (Figure 28.) In the second biopsy the GBM 
showed significantly more thickening as well as several areas 
of splitting of the basement membrane. The electron 
micrographs showed several areas of mesangial 
interposi tioning. The third biopsy, performed 5 years after 
the first showed only occasional membrane spiking, but very 
extensive basement membrane splitting or reduplication. On 
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light microscopy the appearances were of mesangiocapillary 
glomerulonephritis. The deposits seen on electron microscopy 
seemed to be divided into 2 populations. Some appeared older 
and were fading while others appeared to be of more recent 
origin (figure 32). 
Figure 28. Methenamine silver stain of the first biopsy of 
patient 42 
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Patient 56 underwent his first biopsy within a month of onset 
of symptoms. This showed stage 2 to 3 membranous nephropathy 
with segmental sclerosis affecting 11 of 20 glomeruli. One 
year later he had progressed to chronic renal failure and 
repeat biopsy showed diffuse global sclerosis. The third 
biopsy was performed on the graft kidney 8 months after 
transplantation because of an acute rejection episode. There 
was no evidence of recurrent membranous nephropathy. 
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Figure 29. Methenamine silver stain of the second biopsy from 
patient 42, taken 32 months after the biopsy shown in figure 
28. There are several areas where the GBM is split and in 
others a "chain-link" effect can be seen. Spikes can still be 
seen in some areas. 
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Figure 30. Electron micrograph from the same biopsy as figure 
29. There are numerous intramembranous and occasional 
subepithelial immune complexes visible. In areas there is 
interpositioning of mesangial cell cytoplasm between the GBM 
and the endothelial cell with subsequent "splitting" of the 
GBM. 
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Figure 31. Methenamine silver stain of the third biopsy from 
patient 42. The GBM is massively thickened in areas with 
extensive splitting. 
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Figure 32. Same biopsy as figure 31. A polymorphonuclear 
leucocyte occupies the capillary lumen. Numerous subepithelial 
deposits and extensive mesangial interpositioning are shown. 
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ANALYSIS OF FACTORS AFFECTING OUTCOME 
Using stepwise logistic regression analysis, an attempt was 
made to construct models to predict the duration of 
symptomatic disease and changes in calculated GFR. No 
meaningful models could be constructed using age at onset, 
sex, centile of height for age, calculated GFR at diagnosis, 
degree of proteinuria, stage of membranous nephropathy, or the 
degree of GBM splitting or mesangial interpositioning. The 
best correlation with duration of symptoms was with the 
interval from onset of symptoms to the first negative test for 
HBeAg. However, the correlation was rather weak (adjusted r 
squared= 0,21). 
There were too many missing values to be able to calculate 
models using proteinuria selectivity index, complement levels, 
circulating immune complex levels, anti-DNA antibodies or 
anti-nuclear factor titres. 
Using multiple regression analysis, no correlation could be 
found between any of the above factors and either duration of 
nephrotic syndrome or change in GFR. The best correlation was 
with seroconversion to the HBeAg negative state but even this 
failed to reach statistical significance (p = 0,06). 
Hsu et al found that patients without focal glomerular 
sclerosis entered remission earlier than those with 
sclerosis43 • In this study there was no difference in average 
time to asymptomatic proteinuria only (25 vs 23 months) or 
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complete remission (38 vs 30 months). Nor was the presence of 
focal sclerosis useful in predicting declining GFR. As a test 
for estimated GFR of less than 80 ml/min/1,73m2 at last 
follow-up, the presence of focal sclerosis had a sensitivity 
of 25% and a positive predictive value of 30%. The specificity 
was 88% and the negative predictive value 85%. 
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DISCUSSION 
Clinical and demographic data 
This confirms the 4: 1 ratio described by Wiggelinkhuizen on 
the first 25 of these children8 and should be compared with 
the 1,4:1 ratio found in idiopathic membranous nephropathy in 
children44 , and a ratio of 1,5:1 for all patients with 
nephrotic syndrome in our series. Most other authors have 
described a similar large male predominance43145 , although a 
few have described a more equal distribution4121 • Venkataseshan 
et al described only 12 patients, including 5 over the age of 
21 years21 • In the study by Brzosko et al there was no 
dominant histopathological type, and the question of 
coincidental HBV infection must arise4 • 
The reason for this sex distribution is probably a greater 
frequency of HBV infection in boys19146- 4748 • Although there are 
no data regarding the prevalence of HBV infection in the 
Western Cape, this postulate is supported by data from the 
Gastroenterology Unit at Red Cross War Memorial Children's 
Hospital. Of 23 patients with HBV related chronic active 
hepatitis, 19 (83%) were boys (W.J. Frischman, personal 
communication.) 
The average age of onset was 6,58 years. Again this is similar 
to the pattern described by other authors45 , although some 
have described a slightly earlier peak incidence, at about 4-5 
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years. 11143 • It is probable that the age pattern simply 
reflects the age at which HBV infection is acquired. 46147149 • 
No data are available concerning the epidemiology of HBV 
infection in the Western Cape, and it is known that patterns 
of infection may differ widely in different areas. 46148 • The 
average age of presentation of children with chronic active 
hepatitis was 6, 3 8 years, again suggesting that this is the 
average age of acquisition of HBV infection in the population 
served by this hospital. 
The transmission of HBV infection is mainly horizontal in 
Africa46147150 • The age of onset of disease in the current 
study is also compatible with horizontal spread of infection. 
In addition, 62% of mothers tested had no evidence of present 
or past HBV infection. Horizontal transmission was felt to be 
the principal method of infection in other studies as well, 
even in the Far East where vertical transmission is more 
common. 431 51 
The stunting seen in the patients in this series is probably 
not related directly to their renal disease, but reflects the 
nutritional status of a large part of the community served by 
Red Cross War Memorial Children's Hospita152153 , and are 
similar to the results of surveys of nutritional status 
carried out in the outpatient department of this hospital over 
several years54 • This study did not compare growth parameters 
of children with HBV related renal disease with other patients 
with nephrotic syndrome or glomerulonephritis, but it would be 
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usefull to do this as further confirmation of that stunting is 
not due mainly to the HBV related disease. 
The majority of patients had oedema, ascites and microscopic 
haematuria. In addition, 26% had hypertension at presentation. 
These signs led to an initial clinical diagnosis of acute post 
streptococcal nephritis in several patients in this series. 
Even in an area with a high prevalence of HBV infection, the 
association of HBV with renal disease appears to be less 
widely appreciated than the association with other 
complications such as hepatocellular carcinoma and even 
polyarteritis nodosa. 
Fourteen (19%) of the patients in this series had TB. Kala et 
al found TB in 37, 5% of 40 patients with focal segmental 
glomerulosclerosis (FSGS) in Johannesburg, and these patients 
had a worse prognosis than those without TB55 • The incidence 
of TB is high in the Western Cape. In addition, the altered 
immune state in the nephrotic syndrome may promote activation 
of TB and impair host defense mechanisms. Alternatively the 
combination of TB and HBV infection may be particularly 
nephritogenic. 
In this series the average change in calculated GFR from 
diagnosis to last follow-up was negligible (-0,5 
ml/min/l.7Jm2 ). One of the 2 patients who developed end stage 
renal failure had pulmonary TB, but none of the other 3 
patients with an estimated GFR of 50 or less had TB. There was 
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no difference in duration of symptoms between those patients 
with TB and those without. There is no evidence from these 
data that TB exerts a significant deleterious effect on the 
course of the disease, either in terms of duration of 
nephropathy or renal function. 
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Laboratory data 
The results of urine microscopy were non-specific. Six 
patients {8%) had completely bland urinary sediments with no 
excess of cells or casts. Five had red cell casts in the 
urine. Of these, 2 
(patients 56 and 
subsequently received Interferon therapy 
64). Patient 56 has been successfully 
transplanted while patient 64 was asymptomatic when last seen, 
but with reduced renal function (calculated GFR 54 
ml/min/1,73m2 ). Two of the other 3 patients entered remission 
after 5 and 11 months respectively, while the third had 
asymptomatic proteinuria only after 31 months. Although there 
were only 5 patients with urinary RBC casts, 2 had significant 
loss of renal function. Red cell casts may be an indicator of 
a more severe inflammatory process in the glomeruli. 
Inaccurate urine collections probably account for much of the 
discrepancy between the 2 methods of estimating renal 
function. In addition, the calculation of GFR was done using 
the first creatinine value obtained, whereas formal clearance 
studies were often not done until days or even weeks later. 
Because calculated GFR was available on nearly all patients 
both at presentation and follow-up, it was used as the major 
method of estimating renal function 
Approximately 25% of patients had impaired renal function 
(calculated GFR less than 80 ml/min/1, 73m2 ) at presentation 
and 12 had reduced GFR at last follow-up. Of the 12, only 4 
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had reduced renal function at presentation. Of the 2 patients 
who progressed to end stage renal failure, 1 had a calculated 
GFR of 36 at presentation, and the other had an estimated GFR 
of 113 ml/min/1,73m2 • 
Two patients had elevated estimated GFRs at presentation (GFR 
greater than 160 ml/min/1,73m2). Both had a normal GFR at last 
follow-up, when both were in remission. 
Estimated GFR was not useful as a predictor of outcome. 
All patients had nephrotic syndrome or heavy proteinuria. The 
proteinuria selectivity index varied widely. There were too 
many missing values to be able to use the selectivity index as 
a prognostic indicator. Seggie et al56 found only 1 of 8 (13%) 
children with HBV associated membranous nephropathy had 
selective proteinuria (selectivity index< 10%). In this study 
proteinuria was selective in 29% of the 34 patients in whom it 
was measured. 
Apart from hepatomegaly, there were no other clinical signs of 
liver disease in these patients. Most had mild elevations of 
ALT which fluctuated during the course of the disease. Three 
liver biopsies all showed mild chronic persistent hepatitis. 
In those reports that include descriptions of liver pathology, 
chronic persistent hepatitis in children and chronic active 
hepatitis or chronic persistent hepatitis in adults are the 
most frequent patterns3•9•12 • 45 • 51 • 57 • Isolated cases have been 
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reported of children with chronic active hepatitis, cirrhosis 
and fulminant hepatitis 7 , 9 , 58 , 59 • 
Patients with symptomatic nephrotic syndrome are almost always 
HBeAg positive. This has been confirmed by most other 
authors9 • 11 • 19- 21 • Seggie et al did not demonstrate HBeAg in any 
of their patients. In this study 34 of 38 patients in 
remission were HBeAg negative and 34 of 39 who were HBeAg 
negative were in remission while the remaining 5 had 
asymptomatic proteinuria only. 
Most patients become HBeAg negative shortly before or after 
entering remission. In this study it was not possible to show 
a very close correlation between remission and seroconversion. 
Possible reasons for this are the irregular nature of HBV 
antigen testing in this retrospective study, and the fact that 
a period of repair to the GBM is likely to be required before 
proteinuria stops. 
The clinical correlation of seroconversion from HBeAg 
positivity to anti-HBe positivity with clearance of the HBeAg 
from the circulation with remission of disease has been noted 
by other authors8•21 • 43 • As in this study, Hsu et al found that 
patients who entered remission tended to lose the HBeAg while 
those whose disease remained active tended to remain 
positive43 • However a direct correlation could not be found. 
Remission occurred in 12 of 13 children before seroconversion, 
105 
but 12 of 16 cases who did not enter remission remained 
positive for HBeAg. 
Milner et al found that HBeAg correlated better with renal 
disease than circulating HBV DNA. HBeAg was present in all 
cases whereas circulating HBV DNA was detected in only 6 of 11 
(54%) 11 • 
The majority of patients had depressed serum complement 
levels, although some had elevated levels. Forty-seven (71% of 
66 patients tested) had total serum complement levels below 
the normal range, while 13 (20%) had levels above the normal 
range. Similar results were obtained for C3 (67% below the 
normal range). The results for C4 were slightly different, 
with 47% below the normal range (p = 0,04 (Chi squared), odds 
ratio 2,3; 95 % confidence limits 1,0-5,1). These results 
suggest that alternate pathway activation of the complement 
cascade occurs more commonly than classical pathway 
activation. 
Low levels of serum C3 and C4 in 15-64% of cases have been 
reported in most studies9•21 • 44 • 56 • A few studies have reported 
normal complement levels5 • 6 • 43 • Lin found low levels of both C3 
and C4 initially, but normal levels of C3 in most after 6 
months with C4 levels tending to remain low in almost 3 0%. 51 
Milner et al found low levels of C3 but not of C4, also 
suggesting alternate pathway activation11 • 
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In this series, 24 of 29 patients {83%) had normal levels of 
circulating immune complexes as assayed by the Clq binding 
assay. Other authors have found elevated levels in their 
patients19 ' 45 • Furose et al found varying levels depending on 
the clinical organ involvement19 • Twenty-five percent of those 
with renal disease alone had elevated CIC's, while 100% of 
those with only liver disease had elevated levels. Lin found 
that 67% of his patients had elevated IgM containing CIC's at 
presentation, but none still had elevated levels after 6 
months51 • IgG and IgA CIC's were not different from controls. 
Lin was also able to demonstrate HBsAg containing CIC's. The 
level did not correlate with the degree of proteinuria or 
haematuria51 • 
HBeAg is known to circulate both in the free form and in 
complexes with IgG60 ' 61 , and Takekoshi et al have postulated 
that these circulating immune complexes may play a central 
role in the pathogenesis of HBV associated nephropathy61 • It 
would appear that these HBeAg-IgG complexes are not detected 
by routine assays for CIC's. 
The increase in size and echogenicity of the kidneys as seen 
on ultrasound scanning is non-specific and compatible with any 
inflammatory process. 
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Clinical course of the disease: 
The majority of patients followed a fairly benign course. The 
median duration of symptomatic proteinuria was under 2 years, 
and about 2 thirds were in complete remission within 5 years. 
A few did have more prolonged symptoms. Thirty-seven patients 
were followed for more than 40 months; 7 still had active 
nephrotic syndrome, and 5 had asymptomatic proteinuria at the 
last visit. Of the 38 patients in complete remission, 5 took 
longer than 40 months to enter remission. Venkataseshan et al 
analysed 8 previous publications and concluded that in 
children about 65% can be expected to be in spontaneous 
remission after 1 year, 85% within 2 years and by 5 to 7 years 
about 95%21 • In the present study the early remission rates 
are somewhat lower. 
Most patients had well preserved renal function, but 2 
progressed to end stage renal failure and 3 others had an 
estimated GFR of under 50 ml/min/1,73m2 • Progression to 
chronic renal failure has been described by several authors. 
An analysis of 5 other studies with a minimum follow-up period 
of 1 year10 , 43 ,si,sG,G2 revealed 10 of 112 (8,9%) children with 
progressive loss of renal function. In this study, 5 of 72 
(6,9%) children had an estimated GFR of less than 50 
ml/min/1,73m2 at last follow-up. Combining the 2 figures gives 
8% of children developing chronic renal impairment. 
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The risk of chronic renal failure appears to be much higher in 
adults, with one third of patients progressing relentlessly to 
renal failure63 • 
steroid therapy was not effective in any of the patients 
receiving it, while it was responsible for severely 
aggravating the hypertension of at least 1 patient. In several 
other studies steroids have been found to be 
ineffective9 • 51 • 56 • 63 • Lin and Lo found that HBV DNA was present 
in patients with HBV associated membranous nephropathy for 12 
months in untreated patients but persisted for up to 3 years 
in those who had received steroid therapy64 • 
Specific anti-viral therapy has shown more promise57 ' 63 • 64 • Of 
the 3 patients treated with alpha interferon in this study, 1 
cleared the HBeAg from the serum, had a significant decline in 
proteinuria with a concomitant rise in plasma albumin and a 
small decline in serum creatinine levels by the time he 
1 showed no defaulted; 1 showed temporary improvement and 
change. If these 3 patients are analysed 
reported by other investigators57 , 63 , 65 , 66 , g 
with patients 
of 16 patients 
the degree of (56%) showed sustained improvement in 
proteinuria and a further 5 had a temporary improvement. Seven 
of the 16 (44%) became negative for HBeAg and entered complete 
remission. This is not significantly different from the 36% 
seroconversion rate reported in a large study of patients 
receiving interferon for hepatitis B liver disease67 • 
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Lin and Lo described significant reductions in urine protein 
excretion rates in all patients treated with a combination of 
adenosine arabinoside and thymic extract, although only 1 of 
24 became negative for HBeAg64 • 
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Histopathology: 
Most authors have described a large majority of patients with 
membranous nephropathy in HBV associated renal disease. The 
current study supports this observation. As in previous 
studies, 9 , 18 • 21 • 45 ' 51 the patients seen at Red Cross War 
Memorial Children's Hospital had heavy deposition of IgG and 
C3 in the glomerular immune complexes. 
There are several features which emerge from this study which 
have either not been mentioned or received only scant 
attention in previous reports. 
In this study there were significant increases in mesangial 
cells and matrix in 93% and 100% of biopsies respectively. 
While some authors21 • 51 • 68 found mesangial proliferation in 50-
100% of their patients with HBV associated membranous 
nephropathy, Yoshikawa et al described it in only 2 of 16 
(12,5) of their patients44 and several other authors make no 
reference to mesangial changes at a1120 , 56 , 63 • 
Mesangial cytoplasmic interpositioning between the GBM and 
endothelium was seen to some degree in 59% of the electron 
micrographs examined, and on light microscopy GBM splitting 
was visible in 58% of cases. In 8 cases there was diffuse, 
global splitting of the GBM, giving the appearance of 
mesangiocapillary glomerulonephritis. The decision to classify 
these lesions as membranous nephropathy might be 
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controversial, but was taken because of the following 
evidence: 
1. The majority of biopsies examined (approximately 60%) 
showed some degree of mesangial interposi tioning. There 
appears to be a continuum ranging from absence of 
interpositioning to circumferential interpositioning in 
virtually all capillary loops with a wide range of 
intermediate cases. It was therefore felt to be 
artificial and rather arbitrary to classify those with 
the most pronounced degree of interpositioning separately 
from the others. 
2. Although the biopsies showed circumferential 
interpositioning as emphasised in the original 
description by Arakawa and Kimelstiel 69 , immune complex 
deposition was heavy in the subepithelial area and 
mesangium with no subendothelial deposits. 
3. There was no difference in outcome in those with 
extensive interpositioning compared with those without 
interpositioning. This is different from the situation 
described by Arakawa, where circumferential 
interpositioning was uniformly associated with 
progression to chronic renal failure69 • 
4. Serial biopsies in patient 42 showed progression from 
stage 2 membranous nephropathy with no interposi tioning 
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in the first biopsy to global interpositioning in the 
third, with an intermediate stage in the second biopsy. 
Yoshikawa et al described minor degrees of mesangial 
interpositioning in 4 of their 16 patients with HBV associated 
membranous nephropathy and 1 of 12 with idiopathic membranous 
nephropathy44 • 
HBsAg and HBcAg were demonstrated in the majority of biopsies 
tested. HBcAg does not appear in the circulation in detectable 
quantities, and its presence in large amounts in the glomeruli 
is enigmatic. HBeAg shares considerable amino-acid homology 
with HBcAg. HBeAg is produced by proteolysis of the 
translation product of the entire pre-core/core open reading 
frame of the HBV DNA. HBeAg consists of 10 amino acids coded 
by the pre-core region and most of the core protein, lacking 
only 3 4 amino-acids at the car boxy terminus 70 ' 71 • The 
polyclonal antibodies used have been shown to have anti-HBeAg 
activity and binding of these antibodies to HBeAg is the 
probable explanation of these results72 • 
Tubuloreticular bodies not been described in previous reports 
of HBV associated nephropathy, with the exception of the paper 
by Mills and Emms. One paper even suggested that they could be 
specific for the nephropathy associated with the acquired 
immune deficiency syndrome (AIDS) 73 • 
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Prognostic indicators: 
No factors which were useful in predicting outcome in 
hepatitis B associated nephropathy could be identified. This 
was a retrospective study and the possibility that a 
prospective study might be able to identify such factors 
cannot be ruled out. 
Useful prognostic indicators would be of great benefit to 
those caring for patients with this disease, particularly as 
specific antiviral therapy becomes available. Those patients 
at highest risk for progressive renal failure or prolonged 
duration of nephrotic syndrome would be able to receive such 
treatment. At present the role of interferon in the treatment 
of HBV related renal disease is not firmly established. The 
disease has a favourable prognosis in most cases, and 
interferon is expensive and has numerous potential side-
effects. 
Brook et al analysed data from 114 patients given interferon 
for chronic HBV infection in an attempt to identify factors 
predictive of a good response to treatment. They concluded 
that negative human immunodeficiency virus (HIV) status, 
chronic active hepatitis on liver biopsy, high serum AST 
levels, a positive history of acute icteric hepatitis and low 
HBV DNA levels were useful predictors of a good response, 
defined as elimination of HBV DNA and HBeAg for at least 12 
months after treatment 74 • If a subset of patients with HBV 
nephropathy could be identified who are both at high risk from 
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their disease and are likely to respond to treatment, the 
expensive anti-viral agents could be used in a highly cost-
effective manner. 
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Pathogenesis of Hepatitis B Associated Membranous Nephropathy: 
The pathogenic mechanisms involved in the development of HBV 
associated nephropathy are unknown. There are 4 possible ways 
in which HBV infection and membranous nephropathy are 
related: 45 
1. Preformed circulating immune complexes containing HBV 
antigens are deposited in the glomerulus. 
2. Immune complexes containing HBV antigens are formed in 
situ in the subepithelial and mesangial areas. 
3. Glomerular deposits of HBV antigen-containing immune 
complexes are not pathogenic and the deposits develop by 
another virus-induced mechanism. 
4. HBV infection and membranous nephropathy are associated 
but the nephropathy is not caused by the viral infection. 
The available evidence for and against these possibilities is 
discused below. 
Preformed circulating immune complexes containing HBV antigens 
are deposited in the glomerulus. 
Circulating immune complexes containing HBV antigens have been 
demonstrated· in some patients with HBV associated 
nephropathy8119 , and HBeAg has been shown to circulate in 
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complexes with IgG61 • For circulating immune complexes to be 
deposited in the subendothelial space they must be small and 
cationic75 • While HBsAg and HBcAg are large (> 106 Daltons) 
and anionic 76 , 77 , HBeAg is small. In the free form it has a 
molecular weight of 19 000 Daltons, and forms complexes with 
IgG with a mass of 45 000 Daltons. Although HBeAg is also 
anionic the immune complexes are cationic78 • Further evidence 
for an important role for HBeAg is that circulating HBeAg 
tends to correlate with disease activity as shown in this 
study. 
However experimental evidence suggests that membranous 
nephropathy is not mediated by circulating immune complexes 
but rather by 1 of a variety of possible mechanisms of in situ 
formation79 , 80 , but they could account for the mesangial 
deposits. 
Immune complexes containing HBV antigens are formed in situ in 
the subepithelial and mesangial areas. 
This would involve the initial trapping of either viral 
antigen or antibodies directed against such antigens in the 
free form in the subepithelial space. Rabbits chronically 
injected with bovine serum albumin develop predominantly 
membranous lesions81 • This is due to initial charge 
interaction between the cationic antigen and the anionic GBM, 
and similar results have been obtained with other cationic 
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antigens82 • All 3 major HBV antigens are anionic, and primary 
trapping of antigen would not occur. 
Cationic IgG antibodies have been shown to become trapped in 
the subepithelial space, and when followed by an infusion of 
the appropriate anionic antigen give rise to subepithelial 
immune complexes83 • In situ formation of immune complexes may 
therefore play a role in the pathogenesis of HBV associated 
membranous nephropathy. 
Glomerular deposits of HBV antigen-containing immune complexes 
are not pathogenic and the deposits develop by another 
virus-induced mechanism. 
The classical experimental model of membranous nephropathy is 
Heyman nephritis84 • In this model, injection of homogenates of 
rat kidney ("active Heyman nephritis") or preformed antibodies 
against renal cortex ("passive Heyman nephritis") induce 
membranous nephritis in rats. The nephritogenic antigen was 
subsequently found to be a proximal tubule microvillar 
glycoprotein with a molecular weight of 330 kilo-Daltons, 
designated "gp330 1185 • Subsequently gp330 was found to be 
present on the surface of glomerular epithelial cells in 
clathrin coated pits on the base of the foot processes where 
they make contact with the GBM85 • In a refinement of the 
passive Heyman nephritis model, membranous nephropathy has 
been induced by the injection of anti-gp330 antibodies85 • 
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A human equivalent of gp330 has been identified in proximal 
tubules but not in the glomerulus. This does not rule out the 
possibility of similar mechanisms being responsible for the 
formation of immune complexes in human membranous nephropathy. 
There is some evidence that certain kidney membrane antigens 
could play a role in membranous nephropathy85 , and Sekar et al 
have identified anti renal membrane antibodies in patients 
with HBV infection and concomitant nephritis86 • A variety of 
other auto-antibodies have also been demonstrated in chronic 
HBV infection45 • 
Given the auto-immune nature of experimental and probably also 
of idiopathic human membranous nephropathy as well as the 
presence of auto-antibodies in chronic HBV infection, an auto-
immune aetiology for HBV associated membranous nephropathy 
cannot be excluded. 
HBV infection and membranous nephropathy are associated but 
the nephropathy is not caused by the viral infection. 
Finally the frequent occurrence of HBV infection in patients 
with membranous nephropathy may not be due to the HBV 
infection or the immunological consequences thereof. An 
underlying immunological abnormality or genetic predisposition 
may increase the likelihood of these patients acquiring both 
diseases independent of each other. While this possibility has 
not been definitely excluded, it seems unlikely for several 
reasons. Firstly membranous nephropathy is far more common in 
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areas of high HBV prevalence such as Africa and the Far East 
than in areas of low prevalence45 • Secondly complete remission 
tends to correlate with clearance of the HBeAg from the serum. 
Finally there are serological and histopathological 
differences between idiopathic membranous nephropathy and the 
form associated with HBV infection44 • 
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CONCLUSIONS: 
HBV infection is a common cause of nephrotic syndrome in 
children in Cape Town. It accounts for at least 13% (and 
possibly more) of all cases of nephrotic syndrome, and almost 
half of all cases in Black children. 
Boys are affected 4 times more frequently than girls. The peak 
incidence is at about 6-7 years of age. These features 
probably reflect the epidemiology of HBV infection. HBV 
associated nephropathy is due mainly to horizontal spread of 
HBV. 
The clinical features are those of nephrotic syndrome. Nearly 
all had some degree of haematuria, and hypertension is present 
in one quarter. Hepatomegaly occurred in 40% and splenomegaly 
in only 11%. These features provide important clinical clues 
to the aetiology when present. The diagnosis must be 
considered in all patients with a nephritic illness associated 
with heavy proteinuria in areas with a high prevalence of HBV 
infection. 
Tuberculosis was commonly associated with HBV nephropathy in 
this series. TB must be carefully excluded in all patients. 
Serum complement levels were depressed in the majority of 
patients, but some had elevated levels. 
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The histopathological features are those of membranous 
nephropathy with associated mesangial proliferation. Mesangial 
interpositioning between the endothelial cells and the GBM was 
seen to some extent in 60% of biopsies, and was extensive in 
11%, giving the light microscopic appearances of 
mesangiocapillary glomerulonephritis. Serial biopsies in 1 
patient showed progression from "pure" membranous features to 
extensive interpositioning with mesangiocapillary features. 
Biopsy of these patients is essential for accurate diagnosis. 
Thirty per cent of patients with nephrotic syndrome and HBV 
infection had lesions other than membranous nephropathy. Nine 
per cent had minimal change nephrotic syndrome and responded 
to steroid therapy without complications related to the HBV 
infection. 
The majority of patients will be asymptomatic after about 2 
years, but some have a much more prolonged course. Renal 
function is well preserved in most patients, but progressive 
renal failure occurs in approximately 6-8% of cases. No useful 
indicators of prognosis could be identified. 
While the ultimate prognosis is good, morbidity is moderately 
high. All the common complications of nephrotic syndrome were 
observed in this series. 
A randomised, controlled trial is required to define the role 
of anti-viral therapy in the treatment of this condition. 
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Until this has been done, supportive therapy only is indicated 
for the majority of patients. This consists of a low salt diet 
with adequate protein intake, cautious use of diuretics, and 
in severely symptomatic patients infusions of salt-poor human 
serum albumin with diuretic cover. 
The immunopathogenesis of HBV associated nephropathy is poorly 
understood and much research remains to be done to elucidate 
the underlying mechanisms. 
Prevention of all the complications of HBV infection by 
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APPENDIX 1: CLINICAL AND LABOROTAY DATA. 
1. Name: 
2. Hospital Number: 
3. Race and sex code: 
4. Date of birth: 
5. Date of onset: 
6. Date referred: 
7. Dry weight (kg): 
8. Weight lost(%): 
9. Centile weight/age: 
10. Height (cm): 
11. Centile height/age: 
12. Centile weight/height: 
13. Oedema at onset?: 
14. Hypertension at onset?: 
15. Ascites at onset?: 
16. Pleural effusion at onset?: 
17. Hepatomegaly at onset?: 
18. Splenomegaly at onset?: 
19. Haematuria at onset?: 




(months prior to onset) 
21. Mother positive (any Ag/Ab)? 
22. Kidney length (Right) (mm) : 
23. Kidney length (Left) (mm) : 
24. Kidneys measured IVP or US?: 
25. Plasma albumin (g/1): 
26. Plasma total protein (g/1): 
27. Plasma cholesterol (mmol/ 1) : 
28. Plasma urea (mmol/1): 
29. Plasma creatinine (µmol/1): 
30. 24 Hr urine protein (g/day): 
31. Proteinuria selectivity index: 
32. Calculated GFR: 
33. Creatinine clearance: 
34. Plasma ALT (U/1): 
35. Plasma LOH (U/1): 
36. Plasma gamma GT (U/1): 
37. Haemoglobin (g/dl): 
38. Mean cell volume (fl): 
39. White cell count (Xl09 /l): 
40. Neutrophils (%): 
41. Lymphocytes (%): 
42. Monocytes (%): 
43. Eosinophils (%): 
44. Basophils (%): 
45. Platelets (x109/l): 
46. Anti-DNase B (titre): 
47. ASO titre: 
48. Group A Strep culture: 
49. Total complement (U/ml): 
50. CJ (mg/dl): 
51. C4 (mg/dl): 




53. Latex agglutination (titre): 
54. Anti-nuclear factor (titre): 
55. Anti-DNA antibodies (µg bound/ml): 
56. Circulating immune complexes: 
(% Clq binding) 
57. Syphilis serology: 
58·. Increased urinary RBC? 
59. Increased urinary WBC? 
60. Urinary granular casts? 
61. Urinary RBC casts? 
62. Urinary hyaline casts? 
63. Urine culture: 











65. Duration of follow-up (months): 
66. Date asymptomatic: 
67. Date of remission: 
68. Interval onset-asympt: 
69. Interval onset-remission: 
70. Proteinuria at last visit: neg - 4+ 
71. Haematuria at last visit: neg - 4+ 
72. Calculated GFR last visit: 
73. Hypertension at last visit?: 
74. Relapses of proteinuria? 
75. Relapses of haematuria? 
76. Other diseases? 
77. Complications of nephrotic syndrome? 
78. Therapy: 
79. Response to therapy: 
80. Complications of therapy: 
81. First HBsAg positive (date): 
82. First HBeAg positive: 
83. Last HBsAg positive: 
84. Last HBeAg positive: 
85. First HBsAg negative: 
86. First HBeAg negative: 
87. Last HBe antibody negative: 
88. First HBe antibody positive: 
89. Comment: 





Biopsy interval (onset to biopsy): 
GLOMERULI: 
Number in biopsy specimen: 
1. Cellular proliferation 































3. Mesangial matrix 
Proliferation none segm/glob 
4. Glomerular lobulation 
Absent: Present: 















None segm/glob focal/diff % affected: 
6. Glomerular necrosis 
None segm/glob 
7. Haematoxyphil bodies 
Absent/present 
focal/diff 
8. Bowman's capsule 
Normal Thickening {0-3) Fibrosis {0-3) Adhesio 
ns {0-3) 
TUBULES: 
Normal Necrosis Atrophy casts Dilatation 
Tubular BM thickening 
INTERSTITIUM: 







Media Necrosis Infiltrate 
Normal Normal Thickening {0-3) Reduplication 
Interpositioning 
2. Epithelial cells: 
3. Foot processes: 
4. Mesangial hypercellularity: (0-3) 
5. Mesangial matrix: 
6. Electron-dense deposits: 






Tubulovesicular bodies: Present/absent 
Other: 
IMMUHOFLUORESCEHCE: 
Not specified Mesangium Capillaries 
IgG 
IgA 
IgM 
C3 
Cl 
C4 
Fibrin 
BBV AHTIGEHS: 
1. HBsAg: 
2. HBcAg: 
FINAL DIAGNOSIS/STAGE: 
Tubules 
